Trevi Therapeutics Inc (TRVI)
US Market

Trevi Therapeutics (TRVI) Stock Price & Analysis


TRVI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.46 - $4.68
Previous Close$2.97
Average Volume (3M)120.65K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$125.60M
Total Debt (Recent Filing)$10.86M
Price to Earnings (P/E)-3.8
Next EarningsMar 22, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.79
Shares Outstanding59,922,945
Standard Deviation0.47
10 Day Avg. Volume32,158
30 Day Avg. Volume120,653
Price to Book (P/B)1.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside158.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Trevi Therapeutics’s price range in the past 12 months?
Trevi Therapeutics lowest stock price was $0.46 and its highest was $4.68 in the past 12 months.
    What is Trevi Therapeutics’s market cap?
    Currently, no data Available
    When is Trevi Therapeutics’s upcoming earnings report date?
    Trevi Therapeutics’s upcoming earnings report date is Mar 22, 2023 which is in 44 days.
      How were Trevi Therapeutics’s earnings last quarter?
      Trevi Therapeutics released its earnings results on Nov 10, 2022. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.01.
        Is Trevi Therapeutics overvalued?
        According to Wall Street analysts Trevi Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Trevi Therapeutics pay dividends?
          Trevi Therapeutics does not currently pay dividends.
          What is Trevi Therapeutics’s EPS estimate?
          Trevi Therapeutics’s EPS estimate is -$0.1.
            How many shares outstanding does Trevi Therapeutics have?
            Trevi Therapeutics has 59,922,943 shares outstanding.
              What happened to Trevi Therapeutics’s price movement after its last earnings report?
              Trevi Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 1.036%.
                Which hedge fund is a major shareholder of Trevi Therapeutics?
                Among the largest hedge funds holding Trevi Therapeutics’s share is Fairmount Funds Management Llc. It holds Trevi Therapeutics’s shares valued at 9M.


                  Trevi Therapeutics Stock Smart Score

                  The Trevi Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Trevi Therapeutics Inc

                  Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Relmada Therapeutics
                  Paratek Pharmaceuticals
                  Lyra Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis